-
-
-
-
-
-
-
Nabriva Therapeutics to Report 2019 Financial Results and Recent Corporate Highlights on March 12, 2020
-
-
-
-
-
-
-
Pre-Open 08/29: (ROX) (NTNX) (GES) Higher (OLLI) (ANF) (BOX) Lower (more...)
-
-
-
-
-
-
-
Nabriva (NBRV) Announces EMA Validation of Marketing Authorization Application for Lefamulin
-
-
-
-
-
-
-
Nabriva Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Nabriva Therapeutics to Present Data at ECCMID Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia (CABP) and CONTEPO™ (fosfomycin for injection) to Treat C
-
-
-
-
-
-
-
Nabriva Therapeutics Provides Update on PDUFA Date for Intravenous CONTEPO™
-
-
-
-
-
-
-
Nabriva Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

